


IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. Army144cont	
In Re Application Of: Hart et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/696,633	Oct. 29, 2003	S. Chen	000041022	1648	7713	
Title: Ebola Virion Proteins Expressed form Venezuelan Equine Encephalitis Virus Replicons						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>						
OR						
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army144cont

In Re Application: Hart et al.



Application No. 10/696,633	Filing Date Oct. 29, 2003	Examiner S. Chen	Customer No. 000041022	Group Art Unit 1648	Confirmation No. 7713
-------------------------------	------------------------------	---------------------	---------------------------	------------------------	--------------------------

Title: Ebola Virion Proteins Expressed form Venezuelan Equine Encephalitis Virus Replicons

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450".

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Signature


Dated: September 29, 2004

Marlana Titus, Reg. No. 35,843
Nash & Titus, LLC
6005 Riggs Road
Laytonsville, MD 20882
(301) 977-7227

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

Army144cont

Application Number

10/696,633

Applicant(s)

Hart et al.

Filing Date

Oct. 29, 2003

Group Art Unit

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	6,340,463 B1	1/22/02	Mitchell et al.	424	263.1	2/18/98

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	B	WO 00/00617	1/6/00	International application	15/40	7/01		
	C	WO 01/016183	3/8/01	International application	C07K	7/01		

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

	D	Volchkov et al., "The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses", FEBS Letters, Vol. 305, No. 3, pages 181-184 (July 1992).
	E	Sanchez et al., "Biochemical Analysis of the Secreted and Virion Glycoproteins of Ebola Virus", J. Virology, Aug. 1998, Vol. 72, pages 6442-6447.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional)	Application Number	
		Army144cont		10/696,633
		Applicant(s)		
		Hart et al.		
		Filing Date	Group Art Unit	
		Oct. 29, 2003	1648	

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
F	Wilson et al., "Epitopes Involved in Antibody-Mediated Protection from Ebola Virus", Science, Vol. 387, March 3, 2000, pages 1664-1666.
G	Ichihashi and Oie, "Neutralizing Epitope on Penetration Protein of Vaccinia Virus", Virology 220, pages 491-494 (1996).
H	Wolffe et al., "A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies", Virology 211, pages 53-63 (1995).
I	Roper et al., "Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene", J. Virology, June 1996, Vol. 70, No. 6, pages 3753-3762.
J	Isaacs et al., "Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope", J. Virology, Dec. 1992, Vol 66, No. 12, pages 7217-7224.
K	Abstract W33-5, "DNA vaccination against poxviruses using combinations of IMV and EEV immunogens", presented July 2000, American Society for Virology Meeting, pages 113.
L	Abstract P23-6, "DNA immunization with the vaccinia L1R and/or A33R genes", July 1998, poster at American Society for Virology meeting.
M	Meyer et al., "Identification of binding sites for neutralizing monoclonal antibodies on the 14-kDa fusion protein of orthodox viruses", Virology 200, Short Communications, pages 778--783 (1994).
N	Czerny and Mahnel, "Structural and functional analysis of orthopoxvirus epitope with neutralizing monoclonal antibodies", J. General Virology (1990), vol. 71, pages 2341-2352.
O	Hooper et al., "DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge", Virology 266, pages 329-339 (2000).
P	Vazquez and Esteban, "Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus", J. Virology, Nov. 1999, Vol. 73, No. 11, pages 9098-9109.
Q	Vazquez et al., "The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal of alpha-helix", J. Virology, Dec. 1998, Vol. 72, No. 12, pages 10126-10137.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army144cont

Application Number

10/696,633

Applicant(s)

Hart et al.

Filing Date

Oct. 29, 2003

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

R

Rodriguez et al., "The vaccinia virus 14-kilodalton fusion proteins forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene", J. Virology, June 1993, Vol. 67, No. 6, pages 3435-3440.

S

Lai et al., "The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals", J. Virology, Oct. 1991, Vol. 65, No. 10, pages 5631-5635.

T

Rodriguez and Esteban, "Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein," J. Virology, Nov. 1987, Vol. 61, No. 11, pages 3550-3554.

U

Rodriguez et al., "Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus", J. Virology, No.v 1985, vol. 56, no. 2, pages 482-488.

V

NCBI PubMed medline, Abstract for Rodriguez et al., "Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus", J. Virology, No.v 1985, vol. 56, no. 2, pages 482-488.

W

Lin et al., "Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo", J. Virology, Apr. 2000, Vol. 74, No. 7, pages 3353-3365.

X

Gordon et al., "A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope", Virology 181, pages 671-686 (1991).

Y

Ichihashi et al., "Identification of a vaccinia virus penetration protein", Virology 202, pages 834-843 (1994).

Z

Demkowicz et al., "Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans", J. Virology, Jan 1992, Vol. 66, No. 1, pages 386-398.

AA

Wilson et al., "Ebola virus: the search for vaccines and treatments", CMLS Cell., Mol. Life Sci., 58 (2001) pages 1-16.

BB

Pushko et al, "Venezuelan Equine Encephalitis virus replicon vector: immunogenicity studies with ebola NP and GP genes in guinea pigs", Vaccines 97, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory Press, 1997, pages 253-258.

CC

Geisbert et al., "Evaluation in nonhuman primates of vaccines against Ebola virus", Perspectives, Emerging Infectious Diseases, Vol. 8, No. 5, May 2002, pages 503-507.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army144cont

Application Number

10/696,633

Applicant(s)

Hart et al.

Filing Date

Oct. 29, 2002

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DD

Pushko et al., "Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus", Vaccine 11 (2000) pages 1-12.

EE

Wilson et al., "Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins", Virology 286, pages 384-390 (2001).

FF

Wilson and Hart, "Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein", J. Virology, March 2001, Vol 75, No. 6, pages 2660-2664.

GG

Maruyama et al., "Recombinant human monoclonal antibodies to Ebola virus", J. Infectious Diseases, 1999, 179 (Suppl 1), pages S235-S239.

HH

Jahrling et al., "Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections", J. Infectious Diseases, 1999, 170 (Suppl 1), pages S224-S234.

II

Volchkov et al., "Release of viral glycoproteins during Ebola virus infection", Virology 245, pages 110-119 (1998).

JJ

GenBank, Database printout, for Sanchez et al., "Ebola virus nucleoprotein, polymerase complex protein (VP35), matrix protein (VP40), glycoprotein (GP), minor nucleoprotein (VP30), and membrane-associated structural protein (VP24), October 14, 1997 (7 pages).

KK

Hevey et al., "Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants", Virology 239, pages 206-216 (1997).

LL

Maruyama et al., "Ebola virus can be effectively neutralized by antibody produced in natural human infection", J. Virology, July 1999, Vol. 73, No. 7, pages 6024-6030.

MM

Wilson et al., "Ebola virus: the search for vaccines and treatments", CMLS, Cell. Mol. Life Sci. 58 (2001), pages 1826-1841.

NN

Maruyama et al., "Recombinant human monoclonal antibodies to Ebola virus", J. Infectious Diseases, 1999, 179 (Suppl 1), pages S235-S239

OO

Sanchez et al., "The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing", PNAS, USA, Vol. 93, pages 3602-3607, April 1996.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army144cont

Application Number

10/696,633

Applicant(s)

Hart et al.

Filing Date

Oct. 29, 2003

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PP

Jahrling et al., "Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses", Arch Virol, 1996 (Suppl) 11, pages 135-140.

QQ

Parren et al., "Pre-and postexposure prophylaxis of ebola virus infectin in an animal model by passive tranfer of a neutraling human antibody," J. Virology, June 2002, Vol. 76, No. 12, pages 6408-6412.

RR

Wilson et al., "Epitopes involved in antobody-mediated protection from ebola virus", Science, Vol. 287, pages 1664-1666, March 3, 2000.

SS

Sanchez et al., "Detection and molecular characterization of ebola viruses causing disease in human and nonhuman primates", J. Infectious Diseases, 1999, Vol. 179 (Suppl. 1), pages S164-S169.

TT

Sanchez et al., "Biochemical analysis of the secreted and virion glycoproteins of ebola virus", J. Virology, Aug. 1998, Vol. 72, No. 8, pages 6442-6447.

UU

Khaw et al., "Technetium-99m labeling of antibodies to cardiac myosin fab and to human fibrinogen", Radiochemistry and Radiopharmaceuticals, J. Nucl. Med., Vol. 23, No. 11, pages 1011-1019, Nov. 1982.

VV

Farid et al., "Idiotypes, paratopes and molecular mimicry", pages 1-5, and "An idiotypic approach for a vaccine against hepatitis B surface antigen", pages 285-300, both in Anti-Idiotypes, Receptors, and Molecular Mimicry, Ivy Springer-Verlag, 1988.

WW

Kabat et al., "Sequence of proteins of immunological interest, Vol. 1, Fifth ed., pages xiv-xix and 33 pages of sequences (1991).

XX

Waldmann, "Manipulation of T-cell responses with monoclonal antibodies", Ann. Rev. Immunol. (1989) 7:407-444.

YY

Kennedy et al., "Review: Protein-protein coupling reactions and the applications of protein conjugates", Clinica Chimica Acts 70 (1976) pages 1-31.

ZZ

"Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, Vol. 256, pages 495-497 (1975).

AAA

Volchkov et al., "Processing of the ebola virus glycoprotein by the proprotein convertase furin", PNAS USA, Vol. 95, pages 5762-5767 (May 1998).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army144cont

Application Number

10/696,633

Applicant(s)

Hart et al.

Filing Date

Oct. 29, 2003

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BBB

Stiles et al., "Production and characterization of monoclonal antibodies against NAJA NAJA ATRA cobrotoxin", Toxicon, Vol. 29, No.10, pages 1195-1204 (1991).

CCC

Feldmann et al., "Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle", Virus Research, 24 (1992) pages 1-19.

DDD

Peters and LeDuc, "An introduction to ebola: the virus nad the disease", J. Infectious Diseases, 1999, Vol. 179 (Suppl 1), pages ix-xvi.

EEE

Kudoyarova-Zubavichene et al., "Preparation and use of hyperimmune serum for prophylaxis and therapy of ebola virus infections", J. Infectious Diseases, 1999, Vol 179 (Suppl 1), pages S218-223.

FFF

Moe et al., "Plaque assay for ebola virus", J. Clinical Microbiology", Apr. 1981, Vol. 13, No. 4, pages 791-793.

GGG

Waldmann, "Manipulation of T-cell responses wit hmonoclonal antibodies", Ann. Rev. Immunol., 1989, Vol. 7, pages 407-444.

HHH

Mikhailov et al., "An evaluation of the possibility of ebola fever specific prophylaxis in baboons", Voprosy Virusologii, No. 2, pages 82-84, 1994.

III

Harlow and Lane, "Antibodies: A Laboratory Manual", Chapter 6, pages 210-213 (Cold Spring Harbor Laboratory, New York) 1988.

JJJ

Schuurs and Van Weemen, "Review" Enzyme-Immunoassay", Clinica Chimica Acta, 81 (1977), pages 1-40.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.